CRN Asks International Trade Commission to Reject Amarin ’s Omega-3 Complaint, Citing Legal Deficiencies, Harm to Public Interest

In two filings submitted to the International Trade Commission, CRN argued that Amarin was “financially motivated” to expand its near monopoly over a subset of omega-3 products; if successful, CRN says, Amarin’s complaint would make it much more difficult and costly for consumers to access those products.
Source: ConsultantLive - Category: Internal Medicine Authors: Tags: Heart Health Omega-3 Regulatory Trends & Business Source Type: news